InfuSystem Holdings (INFU) Liabilities and Shareholders Equity (2010 - 2026)
InfuSystem Holdings' (INFU) quarterly Liabilities and Shareholders Equity came in at $98.7 million in Q1 2026, down 5.39% YoY from $104.3 million in Q1 2025, and down 1.89% on a QoQ basis from $100.6 million in Q4 2025.
InfuSystem Holdings (INFU) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
InfuSystem Holdings (INFU) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $98.7 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 5.39% year-over-year to $98.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $398.9 million (down 5.4% YoY) and the FY2025 annual result came in at $100.6 million, down 2.95% from the prior year.
- Liabilities and Shareholders Equity declined to $98.7 million in Q1 2026, from $100.6 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $108.5 million in Q2 2024 to a low of $98.2 million in Q1 2022.
- A 5-year average of $101.8 million and a median of $102.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity gained 8.44% — and 2025, when it retreated 7.07%.
- Tracing INFU's Liabilities and Shareholders Equity over 5 years: stood at $99.4 million in 2022, then grew by 3.55% to $102.9 million in 2023, then gained by 0.68% to $103.6 million in 2024, then dropped by 2.95% to $100.6 million in 2025, then decreased by 1.89% to $98.7 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $98.7 million (Q1 2026), $100.6 million (Q4 2025), and $98.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 10.74 Bn |
| 10 | InfuSystem Holdings | 244.47 Mn | 243.50 Mn | 21.41 Mn | 97.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.70 Mn |
| Mar 31, 2026 | 98.66 Mn |
| Dec 31, 2025 | 100.56 Mn |
| Sep 30, 2025 | 98.88 Mn |
| Jun 30, 2025 | 100.85 Mn |
| Mar 31, 2025 | 104.28 Mn |
| Dec 31, 2024 | 103.61 Mn |
| Sep 30, 2024 | 105.30 Mn |
| Jun 30, 2024 | 108.53 Mn |
| Mar 31, 2024 | 104.85 Mn |
| Dec 31, 2023 | 102.92 Mn |
| Sep 30, 2023 | 102.07 Mn |
| Jun 30, 2023 | 102.75 Mn |
| Mar 31, 2023 | 102.26 Mn |
| Dec 31, 2022 | 99.39 Mn |
| Sep 30, 2022 | 98.98 Mn |
| Jun 30, 2022 | 98.82 Mn |
| Mar 31, 2022 | 98.24 Mn |
| Dec 31, 2021 | 97.59 Mn |
| Sep 30, 2021 | 94.79 Mn |